Edinburgh Research Explorer

**ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice**

**Citation for published version:**

**Link:**
[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**
Publisher's PDF, also known as Version of record

**Published In:**
Molecular and Cellular Biology

**Publisher Rights Statement:**
2000, American Society for Microbiology. All Rights Reserved

---

**General rights**
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
ets-2 Is a Target for an Akt (Protein Kinase B)/Jun N-Terminal Kinase Signaling Pathway in Macrophages of *motheaten-viable* Mutant Mice

JAMES L. SMITH,1 ALICIA E. SCHAFFNER,1 JOSEPH K. HOFMEISTER,1 MATTHEW HARTMAN,1 GUO WEI,1 DAVID FORSTHOEFEL,1 DAVID A. HUME,3 AND MICHAEL C. OSTROWSKI1*

Department of Molecular Genetics and the Comprehensive Cancer Center1 and Division of Hematology & Oncology,2 Ohio State University, Columbus, Ohio 43210, and Departments of Biochemistry and Microbiology and Centre for Molecular and Cellular Biology, University of Queensland, Brisbane, Australia3

Received 20 March 2000/Returned for modification 4 May 2000/Accepted 8 August 2000

The transcription factor ets-2 was phosphorylated at residue threonine 72 in a colony-stimulating factor 1 (CSF-1)- and mitogen-activated protein kinase-independent manner in macrophages isolated from *motheaten-viable* (*me-v*) mice. The CSF-1 and ets-2 target genes coding for Bcl-x, urokinase plasminogen activator, and scavenger receptor were also expressed at high levels independent of CSF-1 addition to *me-v* cells. Akt (protein kinase B) was constitutively active in *me-v* macrophages, and an Akt immunoprecipitate catalyzed phosphorylation of ets-2 at threonine 72. The p54 isoform of c-jun N-terminal kinase–stress-activated kinase (JNK–SAPK) coimmunoprecipitated with Akt from *me-v* macrophages, and treatment of *me-v* cells with the specific phosphatidylinositol 3-kinase inhibitor LY294002 decreased cell survival, Akt and JNK kinase activities, ets-2 phosphorylation, and Bcl-x mRNA expression. Therefore, ets-2 is a target for phosphatidylinositol 3-kinase–Akt–JNK action, and the JNK p54 isoform is an ets-2 kinase in macrophages. Constitutive ets-2 activity may contribute to the pathology of *me-v* mice by increasing expression of genes like the Bcl-x gene that promote macrophage survival.

Macrophase colony-stimulating factor 1 (CSF-1) and its cognate receptor tyrosine kinase c-fms control the proliferation, differentiation, and survival of cells of the mononuclear phagocyte cell lineage by activating multiple signaling pathways (reviewed in reference 35). One effect of these signaling events in macrophages is the stable, persistent expression of specific genes. For example the urokinase plasminogen activator (uPA) gene (41), the scavenger receptor A (SR) gene (48), and the Bcl-x gene (38) are all targets of CSF-1 action. The ETS family member ets-2 regulates these three CSF-1 target genes (38, 48, 49).

ets-2 is activated by ras-dependent phosphorylation of threonine residue 72, and CSF-1–c-fms signaling leads to persistent phosphorylation of this site (16, 49). Activation of the ras-raf-MEK-1–Erk protein kinase cascade by CSF-1 leads to rapid and persistent phosphorylation of ets-2 in fibroblasts engineered to express exogenous c-fms as well as in macrophage cell lines or primary bone marrow–derived macrophages (BMMs). The MEK inhibitor PD98059 abrogates ets-2 phosphorylation in response to CSF-1–c-fms signaling in the fibroblast model system (16).

One unanswered question is the precise role of ets-2 in CSF-1–c-fms signaling. Does activation of ets-2 by CSF-1 contribute to mitogenic growth, differentiation, or cell survival? Expression of a dominant-negative ets-2 protein in macrophages in transgenic mice resulted in accelerated apoptosis following CSF-1 deprivation (24). In the macrophage cell line BAC1.2F5, overexpression of ets-2 promoted survival of cells in the absence of CSF-1 (38). These observations indicate that ets-2 may be involved in CSF-1-dependent survival of macrophages.

The mouse *motheaten* (*me*) and *motheaten-viable* (*me-v*) mutants are the result of point mutations that affect splicing of transcripts encoded by the src-homology 2 tyrosine phosphatase 1 gene (SHP-1, also termed hematopoietic cell phosphatase) and lead to expression of proteins with greatly diminished tyrosine phosphatase activity (39, 44). These mutant mice accumulate massive numbers of macrophages and neutrophils in the peripheral tissues, including skin, spleen and lung, and subsequently succumb to an interstitial pneumonia (reviewed in reference 7). The *me-v* mutant mice also develop an inflammatory disease resembling rheumatoid arthritis (30). SHP-1 apparently plays a central role in cell signaling events that regulate macrophage-dependent inflammatory responses.

SHP-1 may be a negative regulator of CSF-1 signaling (10). SHP-1 is phosphorylated on tyrosine following CSF-1 stimulation of macrophages, but does not directly bind to ligand-activated c-fms (50). CSF-1 treatment of primary macrophages obtained from *me* mice is reported to result in c-fms hyperphosphorylation, increased phosphorylation of signaling molecules known to be downstream of c-fms, and an increased rate of macrophage proliferation (10). However, another group reported that CSF-1 mitogenic signaling is unaffected in macrophages obtained from *me* or *me-v* mice, but that granulocyte-macrophage (GM)-CSF mitogenic signaling is hyperactivated in such macrophages (23). SHP-1 forms a complex with Janus kinase family members, including JAK2 (22), and also forms a complex with two members of a family of receptors involved in negative regulation in the immune system, PIR-B (p91A) and SHPS-1 (BIT) (6, 42, 46). Integrin-mediated adhesion is reported to be altered in *me-v* macrophages, and this change in cell adhesion correlates with a two- to fivefold increase in phosphatidylinositol 3-kinase (PI 3-kinase) activity in *me-v* cells compared to wild-type cells (33).
Interestingly, it has been reported that CSF-1 does not activate MEK-1 and Erks in primary macrophages obtained from mice homozygous for the me-v mutation, implying a positive role for SHP-1 in CSF-1 activation of MEK-1 and Erks (31). This observation suggests that studying the me-v mouse model might reveal MEK/Erk-independent pathways leading to ets-2 phosphorylation and activation in macrophages. To test this hypothesis, the phosphorylation of ets-2 in primary macrophages derived from me-v mice was analyzed.

The studies reported here provide evidence for constitutive phosphorylation of ets-2 by the PI 3-kinase/Akt pathway in me-v macrophages. These studies indicate that the p54 isoform of JNK (SAPK) can be found in a complex with Akt in macrophages and that p54 JNK likely is an ets-2 kinase active in me-v macrophages. Phosphorylation of ets-2 correlated with expression of previously identified CSF-1 target genes, including the antiapoptotic Bel-x gene (38). In transient transfection assays, the promoter for the mouse Bel-x gene was superactivated over 90-fold by the combination of ets-2 and a membrane-targeted form of Akt. Phosphorylation of ets-2 and activation of target gene expression were found to correlate with increased me-v macrophage survival. In me-v macrophages, both ets-2 phosphorylation and CSF-1-independent cell survival depend largely on a constitutive PI 3-kinase/Akt pathway. These results indicate that constitutive ets-2 activity may contribute to the pathology of me-v mice by regulating expression of genes that promote cell survival in macrophages.

**RESULTS**

Phosphorylation of ets-2 and expression of ets-2 target genes in me-v macrophages are independent of exogenous CSF-1 and Erk activity. CSF-1 stimulates phosphorylation of ets-2 at threonine residue 72 via the raf/MEK/Erk pathway (16). However, the mitogen-activated protein (MAP) kinases Erk-1 and Erk-2 are reported not to be responsive to CSF-1 stimulation of macrophages isolated from me-v mice (31). To examine whether Erk-independent phosphorylation of ets-2 can occur in macrophages, the phosphorylation of ets-2 at threonine residue 72 was monitored in primary macrophages isolated from mice homozygous for the me-v mutation. For these experiments, a polyclonal antibody that specifically recognizes the phosphothreonine 72-modified version of ets-2 was employed (16). Immunochemistry with this antibody demonstrated that low levels of phosphorylated ets-2 were detected in wild-type BMMs deprived of CSF-1, but that nuclear phospho-ets-2 could be readily detected in these cells treated with CSF-1 (Fig. 1A). If nonimmune serum was substituted in the analysis, no histochemical signal was detected (Fig. 1A). Experiments using BMMs derived from me-v mice produced an unexpected result. In these cells, ets-2 was expressed and phosphorylated in a manner independent of addition of exogenous CSF-1 (Fig. 1A).

In order to confirm these results, extracts prepared from both wild-type and me-v macrophages that had been deprived of CSF-1 for 12 h or grown continuously in the presence of CSF-1 were analyzed by Western blotting with the discriminating anti-phospho-ets-2 antibody or a nondiscriminating ets-2 antibody (Fig. 1B, top and bottom panels, respectively). For wild-type cells, the removal of CSF-1 for 12 h resulted in a slight 1.8-fold decrease in ets-2 steady-state levels and a more significant 8-fold decrease in levels of phosphothreonine 72-ets-2 (Fig. 1B, compare lanes 1 and lane 3). In contrast, phosphorylated ets-2 levels in me-v BMMs were insensitive to withdrawal of CSF-1 for 12 h (Fig. 1B, lanes 2 and 4). In addition, ets-2 was phosphorylated in primary macrophages derived from spleens of me-v mice that had been cultured in the absence of CSF-1 for 48 h (Fig. 1B, lanes 5 and 6). Even after 72 h of CSF-1 withdrawal, the amount of phosphorylated ets-2 detected in me-v BMMs did not change (data not shown). The level of phosphorylated ets-2 in me-v macrophages deprived of CSF-1 was equivalent to the levels observed in CSF-1-treated wild-type cells (Fig. 1B, compare lanes 2 and 3).

Immune kinase assays using Erk-specific antibodies corroborated that Erks were not transiently activated following 12 min of CSF-1 treatment of BMMs derived from me-v mice.
FIG. 1. ets-2 is persistently phosphorylated at residue threonine 72 in me-v macrophages. (A) Detection of phosphorylated ets-2 by immunohistochemistry. Cells were grown for 24 h without CSF-1, fixed, and incubated with ets-2 phosphothreonine antibody (–CSF-1) or stimulated for 8 h with 50 ng of CSF-1 per ml prior to fixation and incubation with either the same ets-2 antibody (+CSF-1) or nonimmune serum (NI). The dark nuclear staining indicates reactivity for ets-2 phosphothreonine 72 antibody. WT, wild type. (B) ets-2 phosphorylation detected in nuclear extracts by Western analysis with the same ets-2 antibody as in panel A (top panel) or an antibody that detects ets-2 regardless of phosphorylation status (bottom panel). Extracts were prepared from BMMs derived from wild-type cells (lanes 1 and 3), from BMMs pooled from three me-v mice (lanes 2 and 4), or from spleen macrophages pooled from three me-v mice (lanes 5 and 6). Cells were grown without CSF-1 for 12 h (lanes 1 and 2) or 48 h (lanes 5) or continuously with 50 ng of CSF-1 per ml (lanes 3, 4, and 6). (C) BMMs derived from wild-type or me-v mice, as indicated, were grown without CSF-1 for 16 h and then stimulated with 50 ng of CSF-1 per ml for the times indicated. Erk immune kinase assays were performed by using the ets-2 “pointed” domain recombinant protein substrate. The phosphorylated ets-2 substrate was detected by autoradiography (top panel), while Western blots using an anti-Erk antibody demonstrated that equal amounts of Erks were immunoprecipitated (bottom panel).

FIG. 2. The ets-2 target genes coding for uPA and SR are expressed in a CSF-1-independent fashion in me-v macrophages. Pooled macrophages (three mice) were grown in medium lacking CSF-1 for 24 h (–CSF-1) or stimulated with 50 ng of CSF-1 per ml for 8 h following cytokine starvation (+CSF). Total RNA was prepared and analyzed by Northern blotting. (A) Expression of uPA mRNA in wild-type (WT) BMMs (lanes 1 and 2), me-v (MeV) BMMs (lane 3 and 4), or me-v spleen macrophages (lanes 5 and 6). The arrow indicates the position of the 2.2-kb mRNA for uPA. (B) Expression of SR mRNA in wild-type BMMs (lanes 1 and 2), me-v BMMs (lane 3 and 4), or me-v spleen macrophages (lanes 5 and 6). The arrows indicate the position of the SR type I or type II mRNA (4 and 3.2 kb, respectively). Blots in both panels were reprobed with a mouse γ-actin probe as a control for sample loading (bottom panels).

The results presented above indicated that Erk-independent phosphorylation and activation of ets-2 occurred in me-v macrophages. One potential candidate for the Erk-independent pathway is the PI 3-kinase/Akt pathway. The PI 3-kinase/Akt pathway can be activated in a ras-dependent or ras-independent fashion (17, 34) and has been implicated in growth, differentiation, and survival pathways in many cell types, including myeloid cells (8, 32). Additionally, a recent report demonstrated that membrane-associated PI 3-kinase levels were two- to fivefold higher in me-v macrophages than in wild-type cells (33), a result that we have reproduced in our laboratory (data not shown).

As a first step, Akt immunoprecipitates prepared from the macrophage cell line RAW264 were assayed for ets-2 kinase activity (Fig. 3A). For these experiments, either the characterized Akt substrate histone H2B or a recombinant ets-2 polypeptide corresponding to the “pointed” domain (amino acids 67 to 170) (16) was used as a substrate. In immune kinase assays, Akt immunoprecipitates were able to phosphorylate either histone H2B or the ets-2 substrate following treatment of cells with the cell-permeable tyrosine phosphatase inhibitor pervanadate (3) (Fig. 3A, lane 2 versus lane 1). Phosphorylation of both histone H2B and ets-2 substrates was inhibited by inclusion of the specific PI 3-kinase inhibitor LY294002 in addition to pervanadate (47) (Fig. 3A, lanes 3 and 4, 50 and 100 μM, respectively).

To test whether an Akt immunoprecipitate catalyzed phosphorylation of the ets-2 substrate at residue threonine 72, the wild-type substrate was compared to a substrate that had alanine substituted for threonine at position 72 (16). While the threonine 72 ets-2 protein was a substrate in the Akt immunoprecipitates, the alanine 72 ets-2 substrate was not (Fig. 1C, left panel, wild-type BMMs; right panel, me-v BMMs) (31). Additionally, persistent activation of Erks after 24 h of CSF-1 stimulation (16) was not observed in me-v cells (Fig. 1C).

Two well-defined target genes of the CSF-1/ets-2 pathway in macrophages are those coding for uPA and SR mRNAs. As demonstrated in Fig. 2, the levels of expression of uPA and SR mRNAs were approximately eightfold higher in wild-type BMMs grown in the presence of CSF-1 than those in cells deprived of CSF-1 (Fig. 2A and B, lane 2 versus lane 1). In me-v BMMs, uPA and SR mRNAs were expressed at high levels whether or not CSF-1 was present (Fig. 2A and B, lanes 3 and 4). Levels of expression of uPA and SR mRNAs were also found to be CSF-1 independent in primary spleen macrophages cultured from me-v mice (Fig. 2A and B, lanes 5 and 6). The phosphorylation of ets-2 in me-v macrophages correlated with increased expression of target genes.

An Akt immunoprecipitate catalyzes ets-2 phosphorylation in vitro, and the PI 3-kinase inhibitor LY294002 diminishes levels of phosphorylated ets-2 in vivo. The results presented above indicated that Erk-independent phosphorylation and activation of ets-2 occurred in me-v macrophages. One potential candidate for the Erk-independent pathway is the PI 3-kinase/Akt pathway. The PI 3-kinase/Akt pathway can be activated in a ras-dependent or ras-independent fashion (17, 34) and has been implicated in growth, differentiation, and survival pathways in many cell types, including myeloid cells (8, 32). Additionally, a recent report demonstrated that membrane-associated PI 3-kinase levels were two- to fivefold higher in me-v macrophages than in wild-type cells (33), a result that we have reproduced in our laboratory (data not shown).

As a first step, Akt immunoprecipitates prepared from the macrophage cell line RAW264 were assayed for ets-2 kinase activity (Fig. 3A). For these experiments, either the characterized Akt substrate histone H2B or a recombinant ets-2 polypeptide corresponding to the “pointed” domain (amino acids 67 to 170) (16) was used as a substrate. In immune kinase assays, Akt immunoprecipitates were able to phosphorylate either histone H2B or the ets-2 substrate following treatment of cells with the cell-permeable tyrosine phosphatase inhibitor pervanadate (3) (Fig. 3A, lane 2 versus lane 1). Phosphorylation of both histone H2B and ets-2 substrates was inhibited by inclusion of the specific PI 3-kinase inhibitor LY294002 in addition to pervanadate (47) (Fig. 3A, lanes 3 and 4, 50 and 100 μM, respectively).

To test whether an Akt immunoprecipitate catalyzed phosphorylation of the ets-2 substrate at residue threonine 72, the wild-type substrate was compared to a substrate that had alanine substituted for threonine at position 72 (16). While the threonine 72 ets-2 protein was a substrate in the Akt immune kinase assay, the alanine 72 substrate was not (Fig. 3A, [ets-2 A72 panel]), indicating that the Akt-associated ets kinase activity phosphorylated the same residue of ets-2 as the raf/Erk pathway (16).

To assess whether the Akt pathway could be responsible for the constitutive phosphorylation of ets-2 observed in macrophages isolated from me-v mice, Akt kinase activities were measured in wild-type and me-v macrophages (Fig. 3B). Both histone H2B and ets-2 substrates were used for this analysis, and identical results were obtained for both substrates (Fig. 3B, top panel versus bottom panel). Akt activity increased about threefold following restimulation of wild-type macrophages deprived of CSF-1 in the representative experiment presented (Fig. 3B, lane 2 versus lane 1) and then returned to basal levels following 30 min of CSF-1 treatment (Fig. 3B, lane 3). Pretreatment of cells with LY294002 resulted in a threefold inhibition of CSF-1-dependent Akt activity (Fig. 3B, lane 4). In
 Akt was present in all samples. (B) Akt immune kinase assays were performed with RAW264 cells using histone H2B, ets-2 T72, and ets-2 A72 as substrates (panels as indicated). Akt was isolated from 10^7 cells grown in normal medium (lane 1), treated for 5 min with 300 μM pervanadate (pervan) (lane 2), or treated for 5 min with both 300 μM pervanadate and 50 or 100 μM PI 3-kinase inhibitor LY294002 (LY) (lanes 3 and 4, respectively). The sample in lane 5 is a control in which Akt antibody was not included. The bottom panel is a Western blot performed with the Akt antibody as a sample loading control (bottom panel).

 The threonine 72 ets-2 phosphorylation site is a proline-directed site (PLLP/TP) that is closely related to the optimal Erk phosphorylation site [RXXRXX(T)/S(T)] (2). However, this site is distinct from the consensus Akt substrate site [RXRXXX(T)] (hydrophobic residue) (1). This implied that ets-2 was probably not directly phosphorylated by Akt, but rather by a kinase that coimmunoprecipitated with Akt. The sequence of the ets-2 site suggested that another MAP kinase family member might be a candidate for the Akt-associated kinase. JNKs were selected as the most likely candidates, because there is evidence linking JNK kinase activation to the PI 3-kinase pathway in several cell types (4, 28, 43).

 To determine if JNKs were in a complex with Akt in me-v macrophages, an anti-Akt antibody was used to immunoprecipitate Akt and associated proteins, and the complex was analyzed by Western blotting with an anti-JNK antibody that recognizes all three known JNK family members and their isoforms (see Materials and Methods). The immunoprecipitates were compared to a whole-cell extract prepared from me-v BMMs (Fig. 4A). The analysis demonstrated that both the p54 and p46 major isoforms of JNK were expressed in BMMs and that the p46 isoform was about twofold more abundant than the p54 isoform (Fig. 4A, lane 3). When an Akt immunoprecipitate was analyzed, the p54 JNK isoform was found to be coimmunoprecipitated with Akt, but the p46 isoform was not detected (Fig. 4A, lanes 1 and 2). The association between Akt and JNK was independent of CSF-1 treatment of the cells.

 Immune kinase assays were performed with both anti-Akt and anti-JNK antibodies for immunoprecipitation (Fig. 4B). This analysis demonstrated that the Akt immunoprecipitate contained c-jun N-terminal kinase activity and that this activity was inhibited three- to fourfold by treatment of cells with 100 μM LY294002 (Fig. 4B, top left panel). The JNK immunoprecipitate had histone H2B kinase activity that was inhibited 2.5-fold by LY294002 treatment, indicating that Akt could be coprecipitated with JNK (Fig. 4B, right middle panel). In addition, the JNK immunoprecipitate contained ets-2 kinase activity that was inhibited twofold by LY294002 treatment. These results implied that the p54 isoform of JNK is an ets-2 kinase found in a complex with Akt in macrophages.

 Extracts prepared from wild-type macrophages were examined in order to establish if Akt and p54 JNK were in a complex in normal as well as me-v cells (Fig. 4C). The analysis
revealed that Akt and p54 JNK were in a complex in a CSF-1-independent fashion (Fig. 4C, top panel, lane 1 versus lanes 2 and 3). Immune kinase assays of the Akt immunoprecipitate indicated that JNK activity, measured with c-jun substrate, was rapidly activated three- to fourfold within 5 min of CSF-1 stimulation of cells (Fig. 4C, lanes 2). The Akt-associated JNK activity returned to basal levels within 30 min (Fig. 4C, middle panel, lanes 3). The activation of JNK in the Akt immunoprecipitate in wild-type cells paralleled histone H2B kinase activity to demonstrate that equivalent amounts of JNK were present in untreated and LY294002-treated samples. IP, immunoprecipitate. (C) Wild-type BMMs were deprived of CSF-1 for 24 h (lane 1) and then restimulated with CSF-1 for 5 or 30 min (lanes 2 and 3, respectively). Cell extracts were prepared and incubated with anti-Akt antibody. Half of the Akt immunoprecipitate was analyzed by Western blotting with a JNK antibody (top panel, p54). The other half was assayed for kinase activity by using both the c-jun (middle panel) and histone H2B substrates (lower panel).

FIG. 4. p54 JNK coimmunoprecipitates with Akt and is an ets-2 kinase in me-v macrophages. (A) Akt immunoprecipitates (lanes 1 and 2) were analyzed by Western blotting with the anti-JNK antibody. Cells were grown in the absence of CSF-1 for 24 h (lanes 1) or continuously in the presence of 50 ng of CSF-1 per ml (lanes 2). Whole-cell extracts were also prepared and analyzed on a lane on the same gel (lane 3). The positions of the p54 and p66 JNK isoforms are indicated. (B) Akt (left panels) or JNK (right panels) immune kinase assays performed on me-v macrophages using N-terminal c-jun, ets-2 “pointed,” and histone H2B substrates, as indicated. Cells were grown continually in the presence of 50 ng of CSF-1 per ml and treated with 100 μM LY294002 (LY) for 16 h as indicated. The bottom panel is a Western blot with an anti-JNK antibody to demonstrate that equivalent amounts of JNK were present in untreated and LY294002-treated samples. IP, immunoprecipitate. (C) Wild-type BMMs were deprived of CSF-1 for 24 h (lane 1) and then restimulated with CSF-1 for 5 or 30 min (lanes 2 and 3, respectively). Cell extracts were prepared and incubated with anti-Akt antibody. Half of the Akt immunoprecipitate was analyzed by Western blotting with a JNK antibody (top panel, p54). The other half was assayed for kinase activity by using both the c-jun (middle panel) and histone H2B substrates (lower panel).

**DISCUSSION**

The finding that MEK-1 and Erks were not activated by CSF-1 in me-v BMMs (31) suggested that the me-v model revealed that Akt and p54 JNK were in a complex in a CSF-1-independent fashion (Fig. 4C, top panel, lane 1 versus lanes 2 and 3). Immune kinase assays of the Akt immunoprecipitate indicated that JNK activity, measured with c-jun substrate, was rapidly activated three- to fourfold within 5 min of CSF-1 stimulation of cells (Fig. 4C, lanes 2). The Akt-associated JNK activity returned to basal levels within 30 min (Fig. 4C, middle panel, lanes 3). The activation of JNK in the Akt immunoprecipitate in wild-type cells paralleled histone H2B kinase activity to demonstrate that equivalent amounts of JNK were present in untreated and LY294002-treated samples. IP, immunoprecipitate. (C) Wild-type BMMs were deprived of CSF-1 for 24 h (lane 1) and then restimulated with CSF-1 for 5 or 30 min (lanes 2 and 3, respectively). Cell extracts were prepared and incubated with anti-Akt antibody. Half of the Akt immunoprecipitate was analyzed by Western blotting with a JNK antibody (top panel, p54). The other half was assayed for kinase activity by using both the c-jun (middle panel) and histone H2B substrates (lower panel).

**DISCUSSION**

The finding that MEK-1 and Erks were not activated by CSF-1 in me-v BMMs (31) suggested that the me-v model...
system might provide a unique genetic background that would facilitate identification of Erk-independent signaling pathways that activate ets-2 in response to CSF-1. Analysis of macrophages derived from me-v mice unexpectedly demonstrated that phosphorylation of ets-2 was constitutive and independent of CSF-1 in these cells. In addition, the well-characterized ets-2 target genes coding for uPA, SR, and Bcl-x were constitutively expressed.

Erk-independent phosphorylation of ets-2 and activation of target genes in me-v macrophages were linked to the constitutive activation of the PI 3-kinase/Akt pathway and of an Akt-associated ets-2 (threonine 72) kinase activity. Furthermore, the p54 JNK isoform coimmunoprecipitated with Akt in macrophages and immune kinase assays demonstrated that JNK could catalyze phosphorylation of an ets-2 substrate dependent on PI 3-kinase signaling. Thus, in addition to being a substrate for the Raf/Erk pathway (16), ets-2 is a substrate for a novel PI 3-kinase/Akt/p54 JNK signaling pathway. The PI 3-kinase pathway is transiently activated by CSF-1 in wild-type cells, but is constitutively active in me-v macrophages. These results also highlight a difference between JNK p46 and p54 isoforms and suggest that the extended C-terminal domain of the p54 isoform may be involved in the association between Akt and JNK.

We have previously demonstrated that an epitope-tagged version of p54 JNK2 expressed in fibroblasts was incapable of catalyzing the phosphorylation of ets-2 substrate under conditions in which the PI 3-kinase pathway was not activated (16). JNK2 is reported to bind to the N-terminal portion of c-jun 25 times more efficiently than JNK1, and this direct interaction increases phosphorylation of c-jun by JNK2 relative to JNK1 (25). ets-2 was likely a poor substrate for JNK2 in the previously reported experiments, because it does not directly form a complex with JNK2. Taken with the results presented here, these data suggest the hypothesis that JNK substrate specificity is altered by association with the Akt complex. An adapter protein present in the Akt-JNK complex may recruit ets-2 and allow direct phosphorylation by p54 JNK even in the absence of a high-affinity interaction between ets-2 and JNK. Thus, the
The in vivo substrate range for the 10 characterized JNK isoforms may be dictated by the signaling complex with which they associate, in addition to high-affinity physical interactions with substrates. Further characterization of the Akt-JNK complex in macrophages will determine if this model is valid.

Our results imply that SHP-1 is a negative regulator of the PI 3-kinase/Akt/JNK pathway in macrophages. However, the question of what is the actual substrate for SHP-1 that lies upstream of the PI 3-kinase pathway remains open. The alterations in signaling in cells deficient in SHP-1 function are likely pleiotropic, reflecting that SHP-1 regulates multiple signaling pathways. In addition to c-fms, the GM-CSF receptor, JAK-2, and negative-signaling receptors p91/PIR-B and SHPS-12 have all been reported as substrates for SHP-1 and all can potentially activate the PI 3-kinase/Akt pathway. The outcome of effects on multiple ligand-receptor
pairs is likely aberrant signaling, leading not only to PI 3-kinase–Akt activation, but also to abrogation of MEK-1–Erk signaling.

Recent work has revealed that, in some cell types, the PI 3-kinase/Akt pathway can negatively regulate the Raf/MEK-1–Erk pathway via phosphorylation of regulatory sites within c-ras (36, 51). Our finding that the PI 3-kinase pathway is constitutively upregulated in me-ν macrophages provides a molecular explanation for the lack of CSF-1-dependent MEK-1 and Erk activity in me-ν macrophages. More interestingly, these results demonstrate an additional level of cross talk between these two pathways, the phosphorylation and activation of et-2. At least one nuclear target of Raf-Erk signaling remains phosphorylated and active in spite of the potential negative cross talk with the PI 3-kinase/Akt pathway in me-ν macrophages.

Why is et-2 a target for both Raf and Akt signaling pathways? The data presented here indicate a link between the PI 3-kinase and Akt signaling pathways that promote me-ν macrophage survival and et-2 activation of antiapoptotic targets like Bcl-x. Perhaps the Raf/MEK/Erk and PI 3-kinase/Akt pathways share some common targets that ensure, under the physiological conditions that dictate negative interactions between the two pathways, programmed cell death is not triggered inappropriately. Work demonstrating that the proapoptotic factor BAD may be a target for both of these signaling pathways supports this idea (15, 37).

et-2 is one of several transcription factors that have recently been identified as targets of Akt action in mammalian cells, including forkhead transcription factors, the cyclic AMP-responsive factor CREB, and NF-κB (29). Our finding that the Akt signaling pathway is active in macrophages from motheaten mice and therefore may have implications for understanding the molecular basis of macrophage-mediated damage in human inflammatory diseases such as rheumatoid arthritis (45).

ACKNOWLEDGMENTS

We acknowledge Lori Nelsen for expert technical assistance; Paul Herman (Ohio State University [OSU]) for critical discussions; Clay J.K.H. was supported by a Fellowship from the Lymphoma Research Foundation of America, Inc., and by T-32 Oncology Training grant CA 5880–5893.

REFERENCES


